Reporte Nº3: Seguimiento de uso de Convupidiol en pacientes con Epilepsia refractaria (Farmacoresistente)

2º Reporte de Seguimiento de uso de Convupidiol en pacientes con Epilepsia Refractaria (Farmacorresistente)

CONVUPIDIOL - Seguimiento de uso de Convupidiol® en pacientes con Epilepsia refractaria (farmacorresistente)

Trabajo "Estudio randomizado, placebo controlado para tratamiento con cannabidiol como aad-on en la epilepsia resistente por Esclerosis Tuberosa" Autor: Thiele, E.A et al.

Paper: “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome” By Dr. Orrin Devinsky

Paper: “A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?” By Dr. Helen Cross

Paper: “Cannabis and epilepsy” By Dr. Rhys H. Thomas and Dr. Mark O. Cunningham

Research Letter: “Labeling Accuracy of Cannabidiol Extracts Sold Online” By Marcel O. Bonn-Miller, PhD; Mallory J. E. Loflin, PhD; Brian F. Thomas, PhD

Paper: “Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol” “ By José A. S. Crippa, Ana C. S. Crippa, Jaime E. C. Hallak, Rocio Martín-Santos, and Antonio W. Zuardi”

News article: “Study finds artisanal CBD not as effective as pharmaceutical CBD for reducing seizures” By Doctor Nathan T. Cohen, M.D., of Children's National Hospital in Washington D.C.